Background/Aims: Endothelin-1 (ET-1) and the α 1 -adrenoceptor agonist phenylephrine (PE) activate cAMP response element binding protein (CREB), a transcription factor implicated in cardiac hypertrophy. The signaling pathway involved in CREB activation by these hypertrophic stimuli is poorly understood. We examined signaling pathways for ET-1-or PE-induced cardiac CREB activation. Methods: Western blotting was performed with pharmacological and genetic interventions in rat ventricular myocytes. Results: ET-1 and PE increased CREB phosphorylation, which was inhibited by blockade of phospholipase C, the extracellular-signal-regulated kinase 1/2 (ERK1/2) pathway, protein kinase C (PKC) or Ca 2+ -calmodulin-dependent protein kinase II (CaMKII). Intracellular Ca 2+ buffering decreased ET-1-and PE-induced CREB phosphorylation by ≥80%. Sarcoplasmic reticulum Ca 2+ pump inhibitor, inositol 1,4,5-trisphosphate receptor (IP 3 R) blockers, or type 2 IP 3 R (IP 3 R2) knock-out abolished ET-1-or PE-induced CREB phosphorylation. ET-1 and PE increased phosphorylation of CaMKII and ERK1/2, which was eliminated by IP 3 R blockade/knock-out or PKC inhibition. Activation of CaMKII, but not ERK1/2, by these agonists was sensitive to Ca 2+ buffering or to Gö6976, the inhibitor of Ca 2+ -dependent PKC and protein kinase D (PKD). Conclusion: CREB phosphorylation by ET-1 and PE may be mainly mediated by IP 3 R2/Ca 2+ -PKC-PKD-CaMKII signaling with a minor contribution by ERK1/2, linked to IP 3 R2 and Ca 2+ -independent PKC, in ventricular myocytes.
Introduction
Neurohumoral hormones such as endothelin-1 (ET-1) or the α 1 -adrenoceptor (AR) agonist phenylephrine (PE) stimulate hypertrophic growth of cardiac myocytes [1] . PE and ET-1 commonly activate phospholipase C (PLC) via G q -coupled receptors to produce inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol from phosphatidylinositol 4,5-bisphosphates, thereby inducing IP 3 receptor (IP 3 R)-mediated Ca 2+ release and protein kinase C (PKC) activation [2, 3] . It has been shown in ventricular myocytes that type 2 IP 3 Rs (IP 3 R2), the major IP 3 R subtype, are localized in the nuclear envelope [4, 5] , intercalated discs [6] , and in the dyadic junctional sarcoplasmic reticulum [7] . Nuclear IP 3 Rs-mediated Ca 2+ signal has been proposed to modulate Ca 2+ -calmodulin-dependent protein kinase (CaMK) II (CaMKII), histone deacetylases (HDAC), and calcineurin-NFATc signaling in ventricular myocytes [1, 5, 8] . These mechanisms are implicated in transcriptional regulation of hypertrophy-specific genes [5, [9] [10] [11] [12] . IP 3 R2 proteins are up-regulated in cardiac hypertrophy and failure [13] via positive feedbak regulation of the calcineurin-NFATc signaling pathway [14] .
The adenosine 3',5'-monophosphate (cAMP) response element-binding protein (CREB) functions as a Ca
2+
-and cAMP-regulated transcription factor for certain genes [15, 16] . Phosphorylation of Ser 133 in CREB by different kinases, including protein kinase A, CaMKs, p90 ribosomal S6 kinases and mitogen-and stress-activated protein kinases (MSKs), results in recruitment of the co-activator CREB-binding protein, thus augmenting CREB-induced gene transcription [15] [16] [17] [18] [19] [20] . It has been shown that PE and ET-1 promote CREB phosphorylation in rat cardiac myocytes [21, 22] , but not in mouse perfused heart preparations [23] . CREB phosphorylation is implicated in the regulation of expression of genes involved in cardiac hypertrophic changes [21, 22] . ET-1-or PE-induced CREB phosphorylation was shown to be mediated by either extracellular signal-regulated kinase1/2 (ERK1/2) or p38 mitogen activated protein kinase (MAPK) signaling in rat ventricular myocytes [21, 22, 24] . Because the ERK1/2 cascade involved in the ET-1-or PE-induced cardiac CREB phosphorylation was suppressed by a PKC inhibitor [24] , it was postulated that CREB activation by ET-1 or PE is mediated by PKC-ERK1/2 signaling. However, the role of PKC in regulating CREB phosphorylation, as well as its interacting partner molecules in such hormonal signaling, has been unknown. Although IP 3 R or CaMKII has been known to modulate CREB phosphorylation in other tissues, such as skeletal muscle [25] , neurons [26] , and cholangiocytes [27] , whether IP 3 Rs and CaMKII regulate cardiac CREB phosphorylation has been unclear.
Therefore, in this study, we explored signal transduction pathways responsible for CREB phosphorylation in rat ventricular myocytes under the exposure to ET-1 or PE. We examined the potential roles of intracellular Ca 2+ , IP 3 Rs, PKC, CaMKII, and ERK1/2 using western blotting combined with pharmacological and genetic interventions. We found that CREB phosphorylations stimulated by either ET-1 or PE was mainly mediated by CaMKII, that, in turn, was activated by IP 3 R2-mediated Ca 2+ increase and Ca
-dependent PKC/protein kinase D (PKD) signaling in these myocytes. Unlike this signaling pathway, the ERK1/2 activation by ET-1 and PE was mediated by IP 3 R2 and Ca
-independent PKC, in a manner resistant to Ca 2+ buffering.
Materials and Methods
Single cell isolation and treatment Ventricular myocytes were enzymatically isolated [28] from male Sprague Dawley rats (200-300 g) and from wild-type (WT) and IP 3 R2 knock-out (KO) mice [29] (C57/B6 background, 3-4 months of age, 24-26 g ). This study conforms with the Guiding Principles for the Care and Use of Experimental Animals published by the Korean Food and Drug Administration and Animal and Plant Quarantine Agency in South Korea. The experiments were carried out according to the guidelines laid down by the Chungnam National University Animal Care and Use Committee (Approval No. CNU-00368). Rats or mice were deeply anesthetized with sodium pentobarbital (150 mg/kg, i.p.), the chest cavity was opened, and the hearts were excised. This surgical procedure was carried out in accordance with the university's ethical guidelines. The excised hearts were retrogradely perfused at 7 ml/min through the aorta, first for 3 min with a Ca
2+
-free Tyrode solution composed of (in mM): 137 NaCl, 5.4 KCl, 10 HEPES, 1 MgCl 2 , 10 glucose, and pH 7.3, at 36.5°C; and then with a Ca 2+ -free Tyrode solution containing collagenase (1.4 mg/ml, Type 1, Roche) and protease (0.14 mg/ ml, Type XIV, sigma) for 12 min; and finally with Tyrode solution containing 0.2 mM CaCl 2 for 8 min. The ventricles of the digested heart were then cut into several sections and subjected to gentle agitation to dissociate the cells. The Ca 2+ concentration of Tyrode solution was gradually increased to 2 mM. The cells were then gently resuspended in the Tyrode solution containing ET-1 (100 nM) or PE (100 µM) or other inhibitors and incubated at 37°C for indicated durations.
Western blotting
After stimulation for the desired time periods, cells were solubilized in SDS lysis buffer containing 10 mM Tris-HCl, pH 7.4, 1% (w/v) SDS, 1 mM phenylmethanesulfonyl fluoride, 1 mM Na 3 VO 4 and complete protease inhibitor mixture (Roche Molecular Biochemicals) for 10 min at 70°C, and then triturated several times by passing through a 1-ml syringe and centrifuged at 12,000 g for 10 min. The supernatant was combined with 2 × Laemmli sample buffer (Bio-Rad, Hercules, CA, USA) and heated for 10 min at 70°C. Protein samples were separated by 10% SDS-PAGE and electroblotted on to nitrocellulose membranes. Total CREB, phospho-CREB, CaMKII, phospho-CaMKII, ERK1/2 and phospho-ERK1/2 were detected with antibodies that specifically recognize the proteins -phosphorylated CaMKII: Cell signaling technology, #3361S, rabbit polyclonal Ab) using a standard Western blot protocol. All blots were imaged and quantified using a ChemiDoc XRS densitometer (Bio-Rad).
Statistics
Results are mean ± SEM with significance (P < 0.05) determined using unpaired 2-tailed Student's t test. n indicates the number of Western blotting experiments. [21] and in adult rat ventricular myocytes, respectively [22] . We first confirmed, by western blotting, whether CREB phosphorylation is increased in isolated adult rat ventricular myocytes treated with these agonists, and further investigated hormonal receptors that mediate these responses. Myocytes were incubated with ET-1 (100 nM) or PE (100 μM) for 15 min, because these agonists maximally affected Ca 2+ transients and CREB phosphorylation under these conditions [21, 22] . CREB phosphorylation was significantly enhanced by ET-1 and PE (Fig. 1A) . To estimate the effects of the agonists on phosphorylating potency, the level of the phosphorylated CREB was normalized to the signal for total CREB and then the ratios for agonist-treated samples were normalized again to the ratio for the control (upper graphs in the figures). CREB activation by ET-1 was almost completely suppressed by pre-treating cells with the ET A receptor blocker BQ123 (1 μM, 30 min) (Fig. 1A) . The ET B receptor blocker BQ788 did not affect the ET-1-induced CREB activation (Data not shown). Similarly, CREB phosphorylation by PE was suppressed by ~80% by the α 1 -adrenoceptor antagonist prazosin (5 μM, 10 min) (Fig. 1A) . The residual small increase in CREB phosphorylation after PE stimulation, in the presence of prazosin, may have been mediated by the β-adrenergic receptor [22] . This result indicates that both ET-1 and PE can stimulate CREB phosphorylation in ventricular myocytes, primarily through ET A receptors and α 1 -adrenoceptors, respectively.
Results

ET-1 and PE stimulate CREB phosphorylation through ET
Role of ERK1/2-MSK1 signaling, PLC and CaMKII in ET-1-and PE-induced CREB phosphorylation
It has been previously demonstrated that PE and ET-1 cause MSK1 phosphorylation via PKC-ERK1/2 signaling and p38 MAPKs in adult rat ventricular myocytes [24] . In addition, the ERK1/2-MSK1 signaling cascade mediates the CREB phosphorylation induced by ET-1 in neonatal rat cardiac myocytes [18] and by PE in adult rat ventricular myocytes [22] . We first confirmed in rat ventricular myocytes whether ERK1/2-MSK1 signaling mediates both ET-1-and PE-induced CREB phosphorylation in rat ventricular myocytes. We used PD98059, a drug inhibiting activation of MAPK kinase-1 (also called MEK1 or ERK kinase) and, hence, the activation of MAPKs/ERKs. We also used H89, a drug suppressing several kinases and a potent MSK1 inhibitor [30] . In cells exposed to 100 nM ET-1 or 100 µM PE for 15 min, CREB phosphorylation was increased, and in both cases this was completely inhibited by pre-treatment with H89 (25 µM, 15 min) or PD98059 (10 µM, 10 min) ( Fig. 1B and C) . These results suggest that both ET-1 and PE activate CREB via MEK1-ERK1/2-MSK1 signaling, consistent with the previous reports in neonatal and adult rat ventricular myocytes [21, 22] . Upper panels show comparison of quantitative levels of phosphorylated CREB relative to the total CREB (normalized to control) shown in the Western blot analysis below. Fifty-µg cell extracts were subjected to SDS/PAGE and immunoblotted for phosphorylated CREB (middle panels) and total CREB (lower panels). (A) Ventricular myocytes were unstimulated or exposed to endothelin-1 (ET-1) (100 nM, 15 min) or phenylephrine (PE) (100 µM, 15 min) without and with ET A receptor antagonist BQ123 (1 µM, 30 min; left) or α 1 -adrenoceptor inhibitor prazosin (5 µM, 10 min; right). Four series of experimental results were quantified.
* P < 0.05 vs. each control (untreated).
# P < 0.05 vs. ET-1 (left) or PE (right). (B and C) Ventricular myocytes were either not exposed to inhibitors (control) or pretreated for 15 min with H89 (25 µM), PD98059 (10 µM), or 20 min with KN93 (1 µM), U73122 (5 µM). Then the pretreated cells were exposed to 100 nM ET-1 (B) or 100 µM PE (C) for 15 min. Four series of experimental results were quantified.
* P < 0.05 vs. control (untreated).
Receptors for ET-1 and PE are G-protein coupled and commonly activate PLC signaling, thereby activating IP 3 Rs and PKC and mobilizing intracellular Ca 2+ in cardiac myocytes [2, 3, [31] [32] [33] . Both ET-1 and PE were reported to activate CaMKII in cardiac myocytes, thereby regulating excitation-contraction coupling and gene transcription [5, 34, 35] . However, the role of CaMKII in the enhancement of CREB phosphorylation by ET-1 and PE is not known. We tested its involvement using the CaMKII inhibitor KN93 (1 µM, 20 min). Stimulation of CREB phosphorylation by ET-1 was suppressed to 10%-15% in cells pretreated with KN93 (Fig. 1B) , while the response to PE was inhibited by KN93 to approximately 30% (Fig. 1C) . Stimulation of CREB phosphorylation by ET-1 or PE was eliminated by the PLC inhibition (U73122, 5 µM, 20 min; Fig. 1B and C) . These results suggest that CaMKII and PLC, in addition to the ERK1/2 signaling, may mediate ET-1-and PE-stimulated CREB phosphorylation.
Role of SR Ca 2+ release and IP 3 R2 in the enhancement of CREB phosphorylation by ET-1 and PE
We next examined whether cytosolic Ca 2+ increase plays a role in the enhancement of CREB phosphorylation by α 1 -adrenoceptor and ET A receptor stimulation. When cytosolic Ca 2+ was buffered by loading the cells with BAPTA-AM (10 µM) for 30 min, CREB phosphorylation was only slightly increased, by about 10%, by subsequent stimulation with ET-1. Under this condition, PE-induced CREB phosphorylation was suppressed by about 70%-80% with cytosolic Ca 2+ buffering ( Fig. 2A) . To further examine whether Ca 2+ release from the sarcoplasmic reticulum (SR) plays a role in ET-1-and PE-induced CREB phosphorylation, Ca 2+ in the SR lumen was depleted using the SR Ca 2+ pump inhibitor, thapsigargin (1 M, 10 min). Exposure to thapsigargin alone increased CREB phosphorylation (Fig. 2B) . This effect was similar to that of ET-1 or PE on CREB phosphorylation and might be stimulated by increased Ca 2+ levels caused by decreased cytosolic Ca 2+ uptake into the SR. This result was consistent with previous reports of the Ca 2+ -dependence of CREB phosphorylation
Fig. 2. Roles of global Ca
2+ increase and SR Ca 2+ release in the enhancement of CREB phosphorylation by ET-1 and PE. Ventricular myocytes were either not exposed to interventions (control) or pretreated for 30 min with BAPTA-AM (10 µM; A) or for 10 min with thapsigargin (1 µM: B), and then treated with ET-1 or PE for 15 min. Upper panels show comparison of quantitative levels of phosphorylated CREB relative to the total CREB (normalized to control) shown in the Western blot analysis below. Fifty-µg cell extracts were subjected to SDS/PAGE and immunoblotted for phosphorylated CREB (middle panels) and total CREB (lower panels). Four and five series of experiments were quantified in BAPTA and thapsigargin, respectively.
# P < 0.05 vs. ET-1 (A) or thapsigargin (B). [16] . Application of ET-1 to the cells pre-exposed to thapsigargin did not further increase CREB phosphorylation. PE treatment decreased the CREB phosphorylation levels that had already been increased by thapsigargin (Fig. 2B ). These data indicate that increase in CREB phosphorylation by ET-1 and PE may be mainly caused by intracellular Ca 2+ increase due to SR Ca 2+ release.
To identify the Ca 2+ release pathway responsible for ET-1-or PE-stimulated CREB phosphorylation, we investigated the role of IP 3 Rs, activated by ET A /α 1 -adrenergic receptor signaling. Both ET-1-and PE-induced increases in the CREB phosphorylation were inhibited by treatment of either xestospongin C (10 µM) or 2-APB (3 µM), the IP 3 R blockers ( Fig. 3A and B). Because these inhibitors are not specific for IP 3 Rs [36, 37] , we confirmed the role Fig. 3 . Role of IP 3 R2 in ET-1-and PE-induced CREB phosphorylation. Ventricular myocytes were either not exposed to interventions (control) or pretreated for 45 min with 10 µM xestospongin C (XeC; A; n = 4) or for 30 min with 3 µM 2-APB (B; n = 4), and then treated with ET-1 or PE for 15 min.
# P < 0.05 vs. ET-1. † P < 0.05 vs. PE. Upper panels show comparison of quantitative levels of phosphorylated CREB relative to the total CREB (normalized to control) shown in the Western blot analysis below. Fifty-µg cell extracts were subjected to SDS/PAGE and immunoblotted for phosphorylated CREB (middle panels) and total CREB (lower panels). (C) Western blotting analysis for phosphorylated CREB and CREB in wild-type (WT; n = 3) and IP 3 R2 knock-out (KO; n = 3) mouse ventricular myocytes without and with ET-1 or PE.
* P < 0.05 vs. control (untreated). # P < 0.05 vs. WT ET-1. † P < 0.05 vs. WT PE. Fifty-µg cell extracts were subjected to SDS/PAGE and immunoblotted for phosphorylated CREB (middle panels) and total CREB (lower panels). * P < 0.05 vs. control (untreated). # P < 0.05 vs. ET-1 (A) or PE (B).
of IP 3 Rs in these hormonal responses by using ventricular myocytes from IP 3 R2 KO mice. In WT myocytes, ET-1 or PE treatment consistently increased CREB phosphorylation (Fig. 3C) . In sharp contrast, neither ET-1 nor PE increased the CREB phosphorylation in the IP 3 R2 KO myocytes (Fig. 3C ). In the KO cells, CREB phosphorylation was, instead, decreased by ET-1 or PE (Fig. 3C, right) . This was consistent with the observation on decrease in the level of phosphorylated CREB in the presence of 2-APB alone (Fig. 3B) . These results suggest that IP 3 R2 plays a key role in the increase of CREB phosphorylation under the stimulation of ET A receptors or α 1 -adrenoceptors in ventricular myocytes.
Role of PKC in ET-1-and PE-induced CREB phosphorylation
Previous papers have shown that ERK1/2-MSK1 signaling is an important mediator of the CREB phosphorylation in the presence of ET-1 or PE [21, 22] . In addition, MSK1 activation by these agonists was inhibited by a PKC inhibitor [24] . We also found that increase in CREB phosphoryation by ET-1 and PE was eliminated by inhibitors for ERK1/2 and MSK1 (Fig. 1B and C) . Activation of PKC during stimulation of α 1 -adrenoceptors and ET A receptors could be facilitated by a Ca 2+ increase via activation of IP 3 Rs. Therefore, we examined the potential roles of PKC and other important kinases in CREB activation during these hormonal stimulations. Inhibition of PKC by GF109203X (5 µM, 10 min) completely suppressed CREB phosphorylation induced by ET-1 or PE (Fig. 4A) . However, blockade of protein kinase A (5 µM KT5720, 30 min) or phosphoinositide 3-kinase (50 µM LY294002, 45 min) did not alter ET-1-or PE-induced CREB phosphorylation (Fig. 4) . These results indicate that PKC may be an important mediator for CREB phosphorylation during the stimulation of α 1 -adrenoceptors and ET A receptors. . Fifty-µg cell extracts were subjected to SDS/PAGE and immunoblotted for phosphorylated CaMKII (middle panels) and total CaMKII (lower panels).
# P < 0.05 vs. ET-1.
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Activation of CaMKII by ET-1 and PE via IP 3 Rs and Ca
2+
After finding evidence for suppression of the ET-1-and PE-induced CREB phosphorylation by inhibition of either the CaMKII or the IP 3 Rs (Figs. 1 and 3) , we monitored the phosphorylated form of CaMKII to directly assess its activation in cells treated with these agonists. Both ET-1 and PE significantly increased CaMKII phosphorylation (Fig. 5A) . We further tested whether ET-1-or PE-stimulated CaMKII phosphorylation requires activation of the IP 3 Rs, using their inhibitor 2-APB. Pre-incubation of the ventricular myocytes with 2-APB (3 µM, 30 min) fully suppressed ET-1-induced CaMKII phosphorylation and suppressed PE-induced CaMKII phosphorylation by 70%-80% (Fig. 5A) . Activation of CaMKII by ET-1 and PE was not observed in the cells pre-loaded with BAPTA (10 µM, 30 min) (Fig. 5B) , suggesting role of Ca 2+ increase in CaMKII activation by these agonists. This result indicates that ET-1 and PE may activate CaMKII mainly via an increase in intracellular Ca 2+ through IP 3 Rs activation, and that PE can also cause CaMKII activation, in part, via an IP 3 R-independent pathway. This result is also consistent with a previous report that ET-1 induces CaMKII phosphorylation via IP 3 Rs in rat ventricular myocytes [5] . However, it has also been reported that PE-induced CaMKII phosphorylation is eliminated by PKC blockade in ventricular myocytes [34] . Because our data showed that CREB phosphorylation by ET-1 and PE was sensitive to inhibitors of either PKC or CaMKII (Figs. 1 and 4) , we tested whether PKC was involved in CaMKII activation in cells treated with ET-1 or PE. Pre-incubation of cells with the PKC inhibitor chelerythrine (5 µM, 30 min) abolished CaMKII phosphorylation by ET-1 or PE (Fig. 5C ). Because inhibition of either IP 3 Rs or PKC suppressed most of the CaMKII activation caused by ET-1 and PE, . Fifty-µg cell extracts were subjected to SDS/PAGE and immunoblotted for phosphorylated ERK1/2 (middle panels) and total ERK1/2 (lower panels).
* P < 0.05 vs. control (untreated). # P < 0.05 vs. ET-1 or PE.
PKC may be the downstream molecule that is activated by IP 3 R-Ca 2+ signaling. To test this hypothesis, we repeated our experiments in the presence of the Ca 2+ -regulated PKC (PKC α, β, and µ [PKD]) inhibitor Gö6976 (10 µM, 15 min) [38] . In cells treated with Gö6976, ET-1 or PE did not increase CaMKII phosphorylation (Fig. 5C ). These results support the hypothesis that CaMKII is activated by the Ca 2+ -dependent PKC/PKD via an IP 3 R-mediated Ca 2+ increase after stimulation of either α 1 -adrenoceptors or ET A receptors.
Role of Ca
2+ -independent PKC and IP 3 R2 in ERK1/2 activation by ET-1/PE Because CREB phosphorylation, stimulated by ET-1 or PE, was prevented either by an ERK inhibitor or by PKC inhibitors (Figs. 1 and 4) , we next examined whether ET-1 and PE activate ERK1/2 and the role of PKC in this activation. To estimate ERK1/2 activation, its phosphorylation was measured by western blotting. Application of ET-1 or PE significantly increased levels of phosphorylated ERK1/2 (Fig. 6A) . Inhibition of PKC using GF109203X (5 µM, 10 min) suppressed ET-1-induced ERK1/2 phosphorylation by 60%-70%, while abolishing the effects of PE (Fig. 6A) . Because CaMKII activation by ET-1 and PE was sensitive to blockade of Ca 2+ -dependent PKC/PKD (Fig. 5C) , we further examined whether ERK1/2 phosphorylation under these hormonal stimulations is also affected by Gö6976. Pre-exposure of cells to Gö6976 (10 µM, 15 min) did not alter the enhancement of ERK1/2 phosphorylation by ET-1 or PE (Fig. 6B) , suggesting no role of Ca 2+ -dependent PKC/PKD in ERK1/2 activation by ET-1 or PE. Consistently, inhibition of CaMKII using KN93 (1 µM, 20 min) did not suppress ET-1-or PE-induced ERK1/2 phosphorylation (Fig. 6C) . As we hypothesized, ET-1-or PEmediated ERK1/2 phosphorylation was suppressed by PLC inhibition (U73122; Data not shown for ET-1) or by the ERK1/2 pathway inhibitor PD98059 (10 µM, 15 min) (Fig. 6C) . ERK1/2 phosphorylation was increased in WT mouse ventricular myocytes by ET-1 (100 nM) or PE (100 µM) (n = 3), but slightly decreased in IP 3 R2 KO myocytes by these agonists (n = 3).
* P < 0.05 vs. control (untreated). -buffered myocytes using BAPTA-AM. Quantitative comparison of the level of phosphorylated ERK1/2 normalized to total ERK1/2 in the absence and presence of ET-1 or PE in untreated myocytes and in the BAPTA-AM (10 µM, 30 min) pre-incubated myocytes (n = 4). Fifty-µg cell extracts were subjected to SDS/PAGE and immunoblotted for phosphorylated ERK1/2 (middle panels) and total ERK1/2 (lower panels).
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These results suggest that ET-1 and PE activate ERK1/2 via PLC and Ca
2+
-independent PKC signaling, but not via CaMKII and PKD.
In the next series of experiments, we examined whether IP 3 Rs and Ca 2+ increase regulate ERK1/2 activation under these hormonal stimulations. When IP 3 Rs were suppressed using 2-APB or XeC, ET-1-or PE-induced ERK1/2 phosphorylation was significantly decreased (Fig. 7A) . To know whether the enhanced ERK1/2 phosphorylation in the presence of ET-1 or PE was caused by IP 3 R2, the level of phosphorylated ERK1/2 was compared in agonist-stimulated ventricular myocytes from WT and IP 3 R2 KO mice. In the WT cells, phosphorylated ERK1/2 was higher in the presence of ET-1 or PE (Fig. 7B) . In contrast, ET-1 and PE caused a slight decrease in the level of phosphorylated ERK1/2 in the IP 3 R2 KO cells (Fig. 7B) . When the cytosolic Ca 2+ increase was suppressed by preincubating cells with the Ca 2+ buffer BAPTA-AM (10 µM), ET-1 and PE continued to increase ERK1/2 phosphorylation to levels similar to those without BAPTA (Fig. 7C) . This result suggests that ERK1/2 signaling may be regulated either directly by IP 3 R2 or through local Ca 2+ signaling in a compartment inaccessible to BAPTA.
Discussion
In this study, we demonstrated that ET-1 and PE stimulate CREB phosphorylation in rat ventricular myocytes by activation of ET A receptors and α 1 -adrenoceptors, respectively, through two general effector molecules, CaMKII and ERK1/2, and that CaMKII and ERK1/2 are regulated by IP 3 Rs and PKC through PLC (Fig. 8) . The CREB activation under these agonists was almost completely eliminated by intracellular Ca 2+ buffering using BAPTA or by SR Ca 2+ depletion (Fig. 2) . Interestingly, of the two major effectors activated by ET-1 and PE, the activity of CaMKII, but not ERK1/2, was sensitive to the Ca 2+ buffers (Figs. 5B and 7C), suggesting that Ca 2+ -dependent activation of CaMKII may play a major role in CREB phosphorylation stimulated by ET-1 or PE. Contrasting effects of Gö6976, the inhibitor of Ca 2+ -dependent PKC/PKD, on the activation of CaMKII and ERK1/2 by these agonists further indicate that only CaMKII activity is regulated by Ca 2+ -dependent PKC/PKD (Figs. 5C, 6B and 8). The sensitivity of ERK1/2 phosphorylation to IP 3 R2 KO and its resistance to internal BAPTA suggest that ERK1/2 signaling during the stimulation of ET A receptors and α 1 -adrenoceptors may occur in a separate compartment that is more closely localized with IP 3 R2 and different PKC isozymes. These data also suggest that ERK1/2 signaling is responsible for the portion (10%-20%) of CREB phosphorylation resistant to Ca 2+ buffering during agonist-induced stimulation (Fig. 8) .
Our data provide evidence for the possible role of IP 3 Rs and CaMKII in the regulation of gene expression during the stimulation of ET A receptor and α 1 -adrenoceptor via activation of CREB. So far, there has been no report showing the role of IP 3 R and CaMKII in CREB -independent PKC-ERK1/2 signaling pathway also mediates a smaller portion of CREB phosphorylation under the stimulation of these receptors. IP 3 R2 may play a critical role in the regulation of ERK1/2 activity and the interaction between IP 3 R2 and ERK1/2 appears to occur in a Ca 2+ -independent manner. CaMKII may, in turn, phosphorylate IP 3 R2, thereby negatively regulating its opening [4] . phosphorylation in the heart. It is assumed that Ca 2+ release through the IP 3 R2 occurs around the nucleus, t-tubules and intercalated disks in ventricular myocytes, where IP 3 R2 molecules are localized [4, 6, 7] . Nuclear Ca 2+ , increased via IP 3 R2, is likely to directly regulate nearby CaMKII, known to co-localize with IP 3 R2 in the nuclear envelope in rat ventricular myocytes [4, 5] . Pre-dominant peri-nuclear Ca 2+ signal or loss of inner-nuclear envelope Ca 2+ during the activation of IP 3 Rs using the direct IP 3 R activator, IP 3 BM or adenophostin, has been shown in ventricular myocytes [5, 39, 40] . Thus, it may be assumed that PE and ET-1 increase Ca 2+ in the perinucleus more significantly than in other regions in rat ventricular myocytes. In addition, IP 3 . In the mouse cerebellum, type 1 IP 3 Rs directly interact with ERK1/2 and ERK1/2 reduces IP 3 R1 activity by phosphorylation [43] . However, how ERK1/2 interacts with IP 3 R2 in cardiac myocytes requires further investigation.
In the present study, we demonstrated, for the first time, that CaMKII is critical for CREB activation under stimulation of α 1 -adrenoceptors or ET A receptors in cardiac myocytes. Because CREB activation is implicated in expression of hypertrophic marker genes [5, 35] , our data provide a possible mechanism for CaMKII-mediated cardiac hypertrophy. It was previously reported that CaMKII is activated by both ET-1 [5] and PE [34] . It should be noted, however, that there is some controversy in the activation mechanisms for CaMKII in the presence of ET-1 and PE. ET-1-induced CaMKII activation was removed by IP 3 R blockade [5] , whereas that by PE was suppressed by PKC inhibition [34] . We found that activation of CaMKII by both agonists was suppressed by inhibition of either PKC or IP 3 Rs (Fig. 5A and C). Because treatment with either Ca 2+ buffers or an inhibitor of Ca
2+
-dependent PKC/PKD eliminated both ET-1-and PE-induced CaMKII phosphorylation (Fig. 5B and C) , it is plausible to think that Ca 2+ increase due to the IP 3 R-triggered Ca 2+ releases may facilitate the activity of PKC/PKD, thereby stimulating CaMKII activation in the presence of ET-1 or PE. Recent evidence suggests activation of PKD by ET-1 and PE and role of PKC-PKD signaling in cardiac hypertrophy [44, 45] . Possible role of PKD and/or PKC isozyme(s) in the signaling pathway involving CaMKII-CREB under stimulation of α 1 -adrenoceptors and ET A receptors needs to be investigated.
We found a complete blockade of ET-1-or PE-induced CREB phosphorylation by PD98059, the ERK1/2 pathway inhibitor (Fig. 1B and C) , which appears to be consistent with the previous reports [21, 22] . However, it should be noted that PD98059 itself reduced levels of the phosphorylated forms of both CREB and CaMKII (Fig. 9) . Blockade of CaMKII phosphorylation by PD98059 may suggest that the ERK1/2 pathway may be an upstream signaling for CaMKII activation. However, this is unlikely during stimulation of ET A receptors and α 1 -adrenoceptors, because ET-1-or PE-induced CaMKII phosphorylation, but not that of ERK1/2, was blocked by BAPTA or Gö6976 (Figs. 5-7) . In addition, ET-1-or PEinduced CaMKII phosphorylation in the presence of PD98059 was still higher than CaMKII phosphorylation under PD98059 only (Fig. 9) . Therefore, the pharmacological effects by PD98059 on ET-1-or PE-induced CREB phosphorylation may have been overestimated because of its nonspecific suppression of CaMKII that also mediates CREB phosphorylation. Important new finding in our study is that ERK1/2 activation under the stimulation of ET A receptors and α 1 -adrenoceptors is caused by the IP 3 R2 and Ca
-independent PKC (Figs. 6B and 7B). This ERK1/2 signaling upon activation of ET A receptors or α 1 -adrenoceptors appears to involve different upstream molecules than CaMKII signaling, such as Ca 2+ and PKC isozymes. In addition, ERK1/2 appears to contribute significantly less than CaMKII to CREB activation under prolonged (15 min) stimulation of these hormonal receptors. Considering the previous report showing that ET-1-or PE-induced ERK1/2 phosphorylation reaches a maximum at 1-2 min after application of these agonists, with a gradual decay after the maximum effects [24] , the role of ERK1/2 may be more significant immediately after exposure to ET-1 or PE than it is later.
Although ET-1 and PE have been thought to induce ventricular hypertrophy [1, 5, [9] [10] [11] [12] 46] , signal transduction pathways for their activation of transcriptional regulators were poorly understood. Our study provide new evidence that the transcription factor CREB is activated mainly via IP 3 R2-mediated Ca 2+ release and subsequent PKC/PKD-CaMKII signaling in ventricular myocytes (Fig. 8) . In addition, our data suggest that activation of CREB by ET-1 and PE is also partly regulated by Ca 2+ -independent PKC-and IP 3 R2-dependent ERK1/2 signaling in a separate compartment (Fig. 8) . We propose that IP 3 Rs-PKC-CaMKII-CREB signal transduction may be an important mechanism by which ET-1 and α 1 -adrenergic agonist regulate gene expression of ventricular myocytes.
